News & Events
- 'Turning Science into Business' AI & ML summit: Navigating AI-driven drug discovery
- Transforming Target and Drug Discovery with Visual Biology derived AI Disease Models
- Visual biology AI neural network recognize disease signatures in cellular pathway visualizations
- Leveraging large-scale mRNA biology data to advance disease understanding
- mRNA Is Never Naked: Exploring RBP Target Space & Therapeutic Opportunities
- Technologies developed to study mRNA life cycle
- Exposing hidden targets within the mRNA regulation space
-
BIO CEO & Investor Conference
When:
Where: New York, USAAnima Biotech has participated and presented at the 2019 CEO & Investor Conference.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
-
The 5th Annual LSX World Congress
When:
Where: London, United KingdomAnima Biotech has been invited to participate in a fireside chat titled, “Structuring a Win-Win Platform Technology Deal”, during the 5thAnnual LSX World Congress to share its expertise in identifying, fostering and establishing mutually beneficial collaborations within the life sciences industry.
The conference is the new name for the Biotech and Money/Medtech and Money World Congress. The meeting is a high-caliber, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.
-
Biotech Showcase 2019
When:
Where: San Francisco, USAAnima Biotech has participated and presented at Biotech Showcase 2019.
The investor and networking conference for public and private biotech companies to meet with and present to investors and pharmaceutical executives during the course of the healthcare industry's most important week of the year.
-
Anima Biotech named U.S. deal of the year winner at LifestarsTM Life Science Awards
When:
Award recognizes the transformative potential of Anima’s $1B+ collaboration with Lilly.
Anima Biotech, the leader in the discovery of drugs that specifically control protein translation, has been named winner of the “U.S. Deal of the Year” award at the 2018 Lifestars AwardsTM.
“We are delighted to receive this award, which recognizes the power and potential of our Translation Control Therapeutics platform,” said Yochi Slonim, co-founder and chief executive officer of Anima Biotech. “Our deal with Lilly further validates our approach and our partnering strategy of creating exclusive collaborations around our partners’ chosen targets.”
“Lifestars presented a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s a testament to Anima Biotech’s efforts that this year’s judging faculty commended them in this manner,” said Neil Darkes, Co-CEO, LSX Ltd. And Lifestars.
The international awards brought together more than 300 global life science leaders, investors and deal makers and key stakeholders from the wider ecosystem to recognize the achievements of the industry. Twenty awards were presented during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK and will support UNICEF UK as the official Charity beneficiary. Lifestars formed a signature, evening networking function during the Jefferies Annual Healthcare Conference week in London, Europe's largest healthcare investment banking conference.
About LifestarsTM
The Lifestars Awards are organised by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit www.lsxleaders.com/lifestars-awards
About Anima Biotech
Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. Anima's platform uses patented biology to monitor the process of mRNA translation by ribosomes. Proprietary, cloud-based analysis software then identifies drug candidates that specifically modulate the production of target proteins. We are advancing an internal pipeline across multiple therapeutic areas of high need and partner with Pharma in exclusive collaboration deals around their targets. Our approach has been validated through our $1B+ collaboration with Lilly, 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. -
Jefferies 2018 London Healthcare Conference
When:
Where: London, United KingdomAnima Biotech will participate at Jefferies 2018 London Healthcare Conference.
The event will feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan. -
3rd annual Inv€$tival Showcase in partnership with Jefferies
When:
Where: London, United KingdomAnima Biotech will participate and present at the 3rd annual Inv€$tival Showcase in partnership with Jefferies.
Biotech and Money connects corporates to capital and has partnered with Jefferies for Inv€$tival to showcase the latest investable private and public life science opportunities. -
BIO-Europe 2018
When:
Where: Copenhagen, DenmarkAnima Biotech will participate and present at BIO-Europe 2018. The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 3,800 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners.
-
SACHS Associates 2018
When:
Where: Basel, SwitzerlandAnima Biotech has participated and presented at the 18th Annual Biotech in Europe Forum.
In Addition, Yochi Slonim, Anima Biotech co-founder & CEO, co-chaired the Platform Technologies & Novel Therapeutics Panel.
The Sachs Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry. -
RNA Leaders Europe Congress
When:
Where: Basel, SwitzerlandAnima’s Vice President of Business Development, Gal Gur, Ph.D., will participate in the upcoming congress during in two roundtable sessions, both focused on the topic of, “Target selection – lessons learned from small molecules RNA Biology,” to discuss her learnings from working on target selection in the mRNA biology space. The sessions are taking place on March 14th at 9:05 AM and 9:50 AM CET. Additionally, Gal will give a presentation titled, "Bringing AI to mRNA Biology for the Discovery of mRNA Drugs and Targets,” on March 14th at 11:20 AM CET. The presentation will discuss how Anima’s mRNA Lightning platform can visualize the complete mRNA life cycle from multiple disease models using high content - high throughput mRNA imaging technologies and how it can decode mRNA biology underlying disease phenotypes using AI. She will also discuss the platform’s applications in drug and target discovery, mRNA vaccine optimization, and RNA-based drug optimization with examples and case studies in oncology and immunology.
The RNA Leaders Europe Congress program features scientific tracks covering in-depth development strategies, trends, and technologies across the entire long and small RNA spectrum. The congress provides an opportunity to join key stakeholders to examine new data and case studies, assess the latest technologies and their potential, and forge the collaborations needed to bring new discoveries to market.
-
Oxford Global Discovery Europe
When:
Where: Berlin, GermanyAnima Biotech will participate in the Oxford Global Discovery Europe event as part of Identification and Validation of Novel Targets track of the Conference held in Berlin, Germany. Our head of discovery, Yoni Sheinberger, Ph.D., will give a presentation titled, “mRNA Lighting Platform | Discovery Of mRNA Biology Modulators and Their Mechanisms of Action,” on June 6th at 12:05 p.m. CST.